high-dose chemotherapyresistant multiple myelomaThis report summarizes a broad experience in the treatment of patients with multiple myeloma resistant to standard chemotherapy. The VAD regimen has induced remissions in about 50% of relapsing patients but in only about 25% of previously unresponsive ...
interferon could reduce the proliferative capacity of myeloma cells (Salmon et al., 1983b), and evidence from its use in chronic myeloid leukaemia that lymphoid stem cell populations might be attenuated (Bergsagel et al., 1986) led to trials of interferon as maintenance following chemotherapy. An...
destruction.Multiple myelomais not curable but chemotherapy induces temporary remission. Typically, patients experience repeated episodes of relapse, treatment and remission over several years until the disease can no longer be controlled. Overall 5-year survival formultiple myelomais around 35%. High-...
Multiple myeloma (MM) is a plasma cell malignancy in which monoclonal plasma cells proliferate in bone marrow, resulting in an overabundance of monoclonal paraprotein (M protein), destruction of bone, and displacement of other hematopoietic cell lines. [1] First described in 1848, MM is part of...
Many patients may have sufficiently aggressive myeloma to be considered candidates for stem cell transplantation, which is an intensive, high-dose chemotherapy regimen, followed by infusion of normal donor-matched cells (in the form of an allogeneic stem cell transfusion [rare], or -- more commonl...
The development of chimeric antigen receptor T-cell therapies for multiple myeloma was one of the hottest topics at ASH Annual Meeting and Exposition.The hype surrounding new CAR T-cell therapies for this indication began to build well before data w...
Even with recent advances in therapy regimen, multiple myeloma patients commonly develop drug resistance and relapse. The relevance of targeting the PD-1/PD-L1 axis has been demonstrated in pre-clinical models. Monotherapy with PD-1 inhibitors produced d
She received a bortezomib, lenalidomide, and dexamethasone (VRd) chemotherapy regimen (bortezomib, 1.3 mg/m2 on days 1, 8, and 15; lenalidomide, 25 mg on days 1–14; dexamethasone, 20 mg on days 1, 8, and 15 and subsequently, every 3 weeks). Meanwhile, the patient stopped taking ...
Carfilzomib, pomalidomide, and dexamethasone regimen safe and well tolerated during recent study. Carfilzomib, pomalidomide, and dexamethasone regimen safe and well tolerated during recent study. An experimental treatment option for multiple myeloma may soon offer a new option for patients suffering from ...
EP: 2.Eligibility Factors in Multiple Myeloma Transplant EP: 3.Multiple Myeloma Care: Pharmacist Team Collaboration EP: 4.Multiple Myeloma Regimen Comparisons EP: 5.Pharmacist's Role in Enhancing Multiple Myeloma Care EP: 6.Choosing Multiple Myeloma Regimens EP: 7.Pharmacists' Patient Counseling R...